This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 48/4/664    most recent 01.HYP.0000237974.74488.30v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohtani, K. Articles by Sunagawa, K. Search for Related Content PubMed PubMed Citation Articles by Ohtani, K. Articles by Sunagawa, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stem Cells Related Collections Restenosis Angiogenesis Animal models of human disease Growth factors/cytokines Smooth muscle proliferation and differentiation Mechanism of atherosclerosis/growth factors

(Hypertension. 2006;48:664.)
© 2006 American Heart Association, Inc.

Original Articles

Angiotensin II Type 1 Receptor Blockade Attenuates In-Stent Restenosis by Inhibiting Inflammation and Progenitor Cells

Kisho Ohtani; Kensuke Egashira; Yoshiko Ihara; Kaku Nakano; Kouta Funakoshi; Gang Zhao; Masataka Sata; Kenji Sunagawa

From the Department of Cardiovascular Medicine (K.O., K.E., G.Z., Y.I., K.F., K.N., K.S.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and the Department of Cardiovascular Medicine (M.S.), Graduate School of Medical Sciences, University of Tokyo, Tokyo, Japan.

Correspondence to Kensuke Egashira, Department of Cardiovascular Medicine Graduate School of Medical Science, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail egashira{at}cardiol.med.kyushu-u.ac.jp

The precise mechanism by which angiotensin II type 1 receptor blocker reduces in-stent restenosis in clinical trials is unclear. We, therefore, investigated the mechanism of in-stent neointima formation. Male cynomolgus monkeys and rabbits were fed a high-cholesterol diet and were allocated to untreated control and type 1 receptor blocker groups. Five days after grouping, multilink stents were implanted in the iliac artery. The type 1 receptor blocker reduced the development of in-stent neointima formation by 30% in rabbits and monkeys. To investigate potential mechanisms, we examined the expression of renin-angiotensin system markers, all of which increased in monocytes and smooth muscle-like cells in the neointima and media within 7 days. The type 1 receptor blocker attenuated increased oxidative stress, the enhanced expression of markers of the rennin-angiotensin system and monocyte chemoattractant protein-1, and macrophage infiltration. The effects of type 1 receptor blocker on the differentiation of peripheral blood mononuclear cells into vascular progenitor cells were also examined. Treatment with type 1 receptor blocker suppressed the enhanced differentiation to smooth muscle progenitor cells induced by stenting. The type 1 receptor blocker attenuated in-stent neointima formation by inhibiting redox-sensitive inflammatory changes and by reducing recruitment of the progenitor cells. These potential actions of type 1 receptor blocker on inflammation and progenitor cells constitute a novel mechanism of suppression of in-stent restenosis by type 1 receptor blocker.

Key Words: angiotensin II • oxidative stress • monocytes

This article has been cited by other articles:

				S. Peters, B. Behnisch, T. Heilmann, and C. Richter First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 91 - 95. [Abstract] [PDF]

				S. Lacchini, A. S. Heimann, F. S. Evangelista, L. Cardoso, G. J. J. Silva, and J. E. Krieger Cuff-induced vascular intima thickening is influenced by titration of the Ace gene in mice Physiol Genomics, May 13, 2009; 37(3): 225 - 230. [Abstract] [Full Text] [PDF]

				S. Hagita, M. Osaka, K. Shimokado, and M. Yoshida Oxidative Stress in Mononuclear Cells Plays a Dominant Role in Their Adhesion to Mouse Femoral Artery After Injury Hypertension, March 1, 2008; 51(3): 797 - 802. [Abstract] [Full Text] [PDF]

				C. Schindler, A. Mueller, P. Bramlage, W. Boecking, W. Kirch, and J. Schweizer Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study Angiology, January 1, 2008; 58(6): 710 - 716. [Abstract] [PDF]

				T. Yamada, T. Kondo, Y. Numaguchi, M. Tsuzuki, T. Matsubara, I. Manabe, M. Sata, R. Nagai, and T. Murohara Angiotensin II Receptor Blocker Inhibits Neointimal Hyperplasia Through Regulation of Smooth Muscle Like Progenitor Cells Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2363 - 2369. [Abstract] [Full Text] [PDF]

				R. C.M. Siow and A. T. Churchman Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in Cardiovasc Res, September 1, 2007; 75(4): 659 - 668. [Abstract] [Full Text] [PDF]

				S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]